Rapport Therapeutics, Inc. (RAPP)
26.07
+1.63
(+6.67%)
USD |
NASDAQ |
Nov 09, 16:00
26.03
-0.04
(-0.15%)
After-Hours: 20:00
Rapport Therapeutics Shareholders Equity (Quarterly) : 391.19M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 391.19M |
| June 30, 2026 | 422.93M |
| March 31, 2026 | 471.51M |
| December 31, 2025 | 484.65M |
| September 30, 2025 | 511.62M |
| June 30, 2025 | 263.51M |
| Date | Value |
|---|---|
| March 31, 2025 | 285.84M |
| December 31, 2024 | 305.43M |
| September 30, 2024 | 323.11M |
| June 30, 2024 | 336.89M |
| March 31, 2024 | 195.11M |
| December 31, 2023 | 140.94M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Johnson & Johnson | 81.53B |
| ANI Pharmaceuticals, Inc. | 637.11M |
| Corcept Therapeutics, Inc. | 833.74M |
| Veru, Inc. | 28.38M |
| Eli Lilly & Co. | 40.27B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 418.56M |
| Total Liabilities (Quarterly) | 27.37M |
| Debt to Equity Ratio | 0.024 |
| Current Ratio | 20.07 |
| Net Debt Paydown Yield | 0.03% |